Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Corey Davis ,Ocuphire Pharma ,Iuvo Bioscience ,Mina Sooch ,Nyxol Development Plan ,Oculos Development Services ,Nasdaq ,Ocuphire Pharma Inc ,Meets Primary Endpoint With ,Subjects Returning ,Baseline Pupil Diameter ,Placebo Subjects ,Trial Showing Substantial Benefit ,Accelerating Reversal ,Only Dilation Reversal Drop ,Webcast Today ,Development Plan ,Next Steps ,Mydriasis Market ,Private Securities Litigation Reform Act ,Resume ,Careers ,Cuphire Announces Positive Topline Results From Mira 3 Phase Fda Registration Trial For Nyxol In The Reversal Of Mydriasis ,Iospace ,Advice ,